121 related articles for article (PubMed ID: 23313534)
1. Resource use and economic impact of patients with gout: a multicenter, population-wide study.
Sicras-Mainar A; Navarro-Artieda R; Ibáñez-Nolla J
Reumatol Clin; 2013; 9(2):94-100. PubMed ID: 23313534
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
[TBL] [Abstract][Full Text] [Related]
3. [Study of patients with gout: clinical features in the last 2 years of monitoring].
Sicras-Mainar A; Viana Álvarez R; Galera Llorca J; Granell Villalón M; Navarro-Artieda R
Gac Med Mex; 2012; 148(5):448-56. PubMed ID: 23128886
[TBL] [Abstract][Full Text] [Related]
4. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.
Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV
Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of health care costs and utilization patterns for patients with gout.
Park H; Rascati KL; Prasla K; McBayne T
Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
[TBL] [Abstract][Full Text] [Related]
6. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
Sicras-Mainar A; Navarro-Artieda R; Blanca-Tamayo M; Gimeno-de la Fuente V; Salvatella-Pasant J
Curr Med Res Opin; 2010 Dec; 26(12):2757-64. PubMed ID: 21034375
[TBL] [Abstract][Full Text] [Related]
7. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
9. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
10. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
12. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
13. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
14. Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
[TBL] [Abstract][Full Text] [Related]
15. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
16. [Morbi-mortality and use of recourses after acute coronary syndrome in a Spanish population].
Sicras-Mainar A; Fernández de Bobadilla J; Navarro-Artieda R; Martín I; Varela-Moreno C
Rev Clin Esp; 2011 Dec; 211(11):560-71. PubMed ID: 22088667
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
18. Cost of illness and determinants of costs among patients with gout.
Spaetgens B; Wijnands JM; van Durme C; van der Linden S; Boonen A
J Rheumatol; 2015 Feb; 42(2):335-44. PubMed ID: 25399391
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
20. Diabetic peripheral neuropathy: resource utilization and burden of illness.
Mehra M; Merchant S; Gupta S; Potluri RC
J Med Econ; 2014 Sep; 17(9):637-45. PubMed ID: 24888404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
